1. Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach. (May 2016) Authors: Angwin, Catherine; Pearson, Ewan; Hattersley, Andrew Journal: Practical diabetes Issue: Volume 33:Number 4(2016:May) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. Issue 12 (21st December 2020) Authors: Angwin, Catherine; Jenkinson, Caroline; Jones, Angus; Jennison, Christopher; Henley, William; Farmer, Andrew; Sattar, Naveed; Holman, Rury R; Pearson, Ewan; Shields, Beverley; Hattersley, Andrew Journal: BMJ open Issue: Volume 10:Issue 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. Issue 12 (21st December 2020) Authors: Angwin, Catherine; Jenkinson, Caroline; Jones, Angus; Jennison, Christopher; Henley, William; Farmer, Andrew; Sattar, Naveed; Holman, Rury R; Pearson, Ewan; Shields, Beverley; Hattersley, Andrew Journal: BMJ open Issue: Volume 10:Issue 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. Issue 12 (21st December 2020) Authors: Angwin, Catherine; Jenkinson, Caroline; Jones, Angus; Jennison, Christopher; Henley, William; Farmer, Andrew; Sattar, Naveed; Holman, Rury R; Pearson, Ewan; Shields, Beverley; Hattersley, Andrew Journal: BMJ open Issue: Volume 10:Issue 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. Issue 12 (21st December 2020) Authors: Angwin, Catherine; Jenkinson, Caroline; Jones, Angus; Jennison, Christopher; Henley, William; Farmer, Andrew; Sattar, Naveed; Holman, Rury R; Pearson, Ewan; Shields, Beverley; Hattersley, Andrew Journal: BMJ open Issue: Volume 10:Issue 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. Issue 12 (21st December 2020) Authors: Angwin, Catherine; Jenkinson, Caroline; Jones, Angus; Jennison, Christopher; Henley, William; Farmer, Andrew; Sattar, Naveed; Holman, Rury R; Pearson, Ewan; Shields, Beverley; Hattersley, Andrew Journal: BMJ open Issue: Volume 10:Issue 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. Issue 12 (21st December 2020) Authors: Angwin, Catherine; Jenkinson, Caroline; Jones, Angus; Jennison, Christopher; Henley, William; Farmer, Andrew; Sattar, Naveed; Holman, Rury R; Pearson, Ewan; Shields, Beverley; Hattersley, Andrew Journal: BMJ open Issue: Volume 10:Issue 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗